Evidence map›Paper›PMID 28974618›Full record

ArticlemBio2017

Disarming Fungal Pathogens:

François L Mayer, James W Kronstad

Open access · goldAbstract read
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Biotech (Basel (Switzerland)) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Phytohormone Production by the EndophytePlants (Basel, Switzerland) · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Intestinal bacteria-a powerful weapon for fungal infections treatment.Frontiers in cellular and infection microbiology · 2023
    Review
  18. Article
  19. Article
  20. Emerging Antifungal Targets and Strategies.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

François L MayerDepartment of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-6800-9429
James W KronstadDepartment of Microbiology and Immunology, Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada kronstad@msl.ubc.ca.ORCID 0000-0003-4240-6976
University of British Columbia · CA

Funding

Rapid production of SARS-CoV-2 molecular clones using CRISPR-based yeast recombineeringR01AI100272 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MADHANI, HITEN D · 2012 to 2025
$11.3M
CIHR MOP-13234NIAID NIH HHS R01 AI100272
6 · The paper itself

Abstract

Bacteria interact with each other in nature and often compete for limited nutrient and space resources. However, it is largely unknown whether and how bacteria also interact with human fungal pathogens naturally found in the environment. Here, we identified a soil bacterium,

Indexed as

AntibiosisBacillusBiofilmsCell WallChitinasesCryptococcus neoformansHumansMelaninsMicrobial InteractionsVirulence FactorsChitinasesMelaninsVirulence Factorscapsule formationcell wallchitinchitinaseinterspecies interactionmelanization

Identifiers

PMID28974618
PMCPMC5626971
OpenAlexW2763755664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.